26.01.2024 – 10:45
Critical Path Institute
Amsterdam (ots/PRNewswire)
The Critical Path Institute (C-Path) has Dr. Klaus Romero, MD, MS, FCP, as its new Managing Director and Cécile Ollivier, MS, promoted from Managing Director, Europe to Vice President, Global Affairs.
Romero has an impressive 16+ years with C-Path, holding key positions within the company, including Chief Science Officer and Executive Director of the Clinical Pharmacology and Quantitative Medicine Program. His key role in founding and leading the Quantitative Medicine Program highlights his significant contributions to C-Path’s critical drug development initiatives over the years.
Commenting on the appointment, M. Wainwright Fishburn, Jr., Chairman of C-Path, said: “Dr. Romero’s outstanding expertise and leadership have been instrumental in our journey to create and implement groundbreaking scientific and regulatory pathways. His strategic vision fits perfectly with C-Path’s mission to accelerate the development of novel therapies. We are confident he will propel the organization forward into its next phase of global impact and breakthrough innovation.2
“Taking on the role of Executive Director of C-Path is a great honor and a tremendous responsibility,” said Romero. “I am committed to continuing C-Path’s tradition of excellence and innovation to benefit drug development of those in need. This commitment has its roots in my early days at C-Path, inspired by the visionary mentorship and leadership of C-Path’s founder, Dr. Raymond Woosley. Our collective efforts will continue to help change the paradigms of “To change drug development for the benefit of those in need.”
Further information about Dr. Romero’s appointment can be found at this link.
Cécile Ollivier has been a key figure at C-Path since joining as Managing Director in April 2021. In her new role, she will oversee global strategic initiatives, focusing on expanding international collaborations and developing innovative approaches to address complex drug development challenges.
“We are very pleased to announce the promotion of Cécile Ollivier to Vice President of Global Affairs,” said C-Path board member Tomas Salmonson Ph.D., MS. “Cécile Ollivier has made an invaluable contribution to our European operations, and “Her extensive experience in global drug development and regulatory science makes her the ideal fit for this expanded role. Her leadership skills will be critical as we continue our mission to accelerate drug development worldwide.”
With more than 16 years of experience in the healthcare sector, Ollivier has made an important contribution to the development of medicines for children and rare diseases. Her efforts have been recognized internationally, including as an expert at the International Conference on Harmonization (ICH) and as leader of the global pediatric extrapolation strategy. Prior to joining C-Path, Ollivier brought her expertise to the European Medicines Agency (EMA) and the medical device industry, where she focused on the development of digital endpoints in clinical trials.
“I am honored to take on this new role,” said Ollivier. “The opportunity to further impact global healthcare and drive innovation in drug development is a perfect fit for my passion and experience. I look forward to working with our talented team and our partners around the world to work together to improve the lives of people and families affected by diseases of unmet need.”
For more information about Ollivier’s promotion, see this link.
Information about the Critical Path Institute
The Critical Path Institute (C-Path) is an independent, nonprofit organization founded in 2005 as a public-private partnership in response to the FDA’s Critical Path Initiative. C-Path’s mission is to initiate collaborations that enable better treatments for people worldwide. As a globally recognized pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives, currently involving more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations, and pharmaceutical and biotech -Companies are involved. C-Path’s global headquarters is in Tucson, Arizona and C-Path’s European office is headquartered in Amsterdam, Netherlands, with dedicated team members located around the world. For more information, visit c-path.org.
Contact:
Roxan Triolo Olives
C-Path
520.954.1634
[email protected] – https://mma.prnewswire.com/media/2326911/Critical_Path_Institute_klaus_web.jpg
Photo – https://mma.prnewswire.com/media/2326910/Critical_Path_Institute_cecile_olivier_petal.jpg
Logo – https://mma.prnewswire.com/media/1180189/Critical_Path_Institute_Logo.jpg
View original content:
Original content from: Critical Path Institute, transmitted by news aktuell